Lysergic acid diethylamide induces increased signalling entropy in rats' prefrontal cortex. [PDF]
J Neurochem, 2022 Psychedelic drugs are gaining attention from the scientific community as potential new compounds for the treatment of psychiatric diseases such as mood and substance use disorders. The 5-HT2A receptor has been identified as the main molecular target, and
Savino A, Nichols CD.
europepmc +4 more sources
Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited. [PDF]
ACS Pharmacol Transl SciLisuride is a non-psychedelic serotonin (5-HT) 2A receptor (5-HT2A) agonist and analogue of the psychedelic lysergic acid diethylamide (LSD). Lisuride also acts as an agonist at the serotonin 1A receptor (5-HT1A), a property known to counter psychedelic ...
Glatfelter GC +4 more
europepmc +4 more sources
Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience [PDF]
PharmaceuticalsLysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects.
Hossein Omidian, Alborz Omidian
doaj +3 more sources
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects [PDF]
Clinical Pharmacokinetics, 2017 Background and ObjectiveLysergic acid diethylamide (LSD) is used recreationally and in clinical research. The aim of the present study was to characterize the pharmacokinetics and exposure–response relationship of oral LSD.MethodsWe analyzed ...
Andrea Eva Steuer +2 more
exaly +4 more sources
Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. [PDF]
Psychol Med, 2023 The non-selective serotonin 2A (5-HT2A) receptor agonist lysergic acid diethylamide (LSD) holds promise as a treatment for some psychiatric disorders. Psychedelic drugs such as LSD have been suggested to have therapeutic actions through their effects on ...
Kanen JW +7 more
europepmc +2 more sources
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. [PDF]
Proc Natl Acad Sci U S A, 2021 Significance Social behavior (SB) is a fundamental hallmark of human interaction. Repeated administration of low doses of the 5-HT2A agonist lysergic acid diethylamide (LSD) in mice enhances SB by potentiating 5-HT2A and AMPA receptor neurotransmission ...
De Gregorio D +14 more
europepmc +2 more sources
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. [PDF]
Mol PsychiatryPsychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders.
Avram M +12 more
europepmc +2 more sources
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. [PDF]
Clin Pharmacol Ther, 2021 “Microdoses” of lysergic acid diethylamide (LSD) are used recreationally to enhance mood and cognition. Increasing interest has also been seen in developing LSD into a medication. Therefore, we performed a pharmacokinetic‐pharmacodynamic study using very
Holze F +9 more
europepmc +2 more sources
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. [PDF]
Neuropsychopharmacology, 2021 Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD.
Holze F +10 more
europepmc +2 more sources
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. [PDF]
J Psychopharmacol, 2021 Background: Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain.
Ramaekers JG +8 more
europepmc +2 more sources